Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Davila

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
Experimental Hematology & Oncology|September 28, 2024
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancersHiroshi Kotani, Tomoyoshi Yamano, Justin C Boucher, et al.
Journal for Immunotherapy of Cancer|July 26, 2022
Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapyNada S Aboelella, Caitlin Brandle, Ogacheko Okoko, et al.
Molecular Therapy Oncolytics|December 11, 2023
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemiaJustin C Boucher, Bishwas Shrestha, Paresh Vishwasrao, et al.
Biorxiv : the Preprint Server for Biology|March 17, 2025
The Th1/Th17 axis regulates chimeric antigen receptor (CAR) T cell therapy toxicitiesPayal Goala, Yongliang Zhang, Cooper Sailer, et al.
Leukemia & Lymphoma|October 19, 2017
Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cellsMark B Geyer, Shwetha H Manjunath, Andrew G Evans, et al.
Transplantation and Cellular Therapy|March 6, 2023
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular LymphomaNing Dong, Lucía Rubio Lopes-Garcia, David Viñal, et al.
The Journal of Clinical Investigation|May 22, 2020
Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host diseaseBishwas Shrestha, Kelly Walton, Jordan Reff, et al.
Cancer Immunology Research|November 14, 2024
Correction: CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell FunctionJustin C Boucher, Gongbo Li, Hiroshi Kotani, et al.
Cancer Immunology Research|November 14, 2020
CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell FunctionJustin C Boucher, Gongbo Li, Hiroshi Kotani, et al.
Journal of the Neurological Sciences|January 30, 2026
Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-celMegan M Herr, Nisha M Nair, Theresa Hahn, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Experimental Hematology & Oncology|September 28, 2024
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancersHiroshi Kotani, Tomoyoshi Yamano, Justin C Boucher, et al.
Journal for Immunotherapy of Cancer|July 26, 2022
Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapyNada S Aboelella, Caitlin Brandle, Ogacheko Okoko, et al.
Molecular Therapy Oncolytics|December 11, 2023
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemiaJustin C Boucher, Bishwas Shrestha, Paresh Vishwasrao, et al.
Biorxiv : the Preprint Server for Biology|March 17, 2025
The Th1/Th17 axis regulates chimeric antigen receptor (CAR) T cell therapy toxicitiesPayal Goala, Yongliang Zhang, Cooper Sailer, et al.
Leukemia & Lymphoma|October 19, 2017
Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cellsMark B Geyer, Shwetha H Manjunath, Andrew G Evans, et al.
Transplantation and Cellular Therapy|March 6, 2023
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular LymphomaNing Dong, Lucía Rubio Lopes-Garcia, David Viñal, et al.
The Journal of Clinical Investigation|May 22, 2020
Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host diseaseBishwas Shrestha, Kelly Walton, Jordan Reff, et al.
Cancer Immunology Research|November 14, 2024
Correction: CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell FunctionJustin C Boucher, Gongbo Li, Hiroshi Kotani, et al.
Cancer Immunology Research|November 14, 2020
CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell FunctionJustin C Boucher, Gongbo Li, Hiroshi Kotani, et al.
Journal of the Neurological Sciences|January 30, 2026
Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-celMegan M Herr, Nisha M Nair, Theresa Hahn, et al.
Pageof 13